Notably, this study proposes a novel therapeutic treatment based on NAMNT-2 depletion or PARP16 inhibition relying on the strategical approach to target the NAD+ availability in cancer cells, thereby affecting the downstream NAD+-consuming enzymatic pathways. Here, PARP16 is linked to cancer.